These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 32555927)

  • 1. Short-term efficacy and safety of levosimendan in patients with chronic systolic heart failure.
    Cui XR; Yang XH; Li RB; Wang D; Jia M; Bai L; Zhang JD
    Cardiovasc J Afr; 2020; 31(4):196-200. PubMed ID: 32555927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy and safety of levosimendan in elderly patients with severe heart failure].
    Wang YB; Yu YH; Gong SJ; Yan J; Wang Y
    Zhonghua Nei Ke Za Zhi; 2020 Jun; 59(6):433-438. PubMed ID: 32486583
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan Can Improve the Level of B-Type Natriuretic Peptide and the Left Ventricular Ejection Fraction of Patients with Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials.
    Cui D; Liao Y; Li G; Chen Y
    Am J Cardiovasc Drugs; 2021 Jan; 21(1):73-81. PubMed ID: 32462455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of simendan in the treatment of acute heart failure and its impact on NT-proBNP.
    Li J; Wang XY; Yang ZY; Li Y; Yang F; Yuan P; Yang J
    Eur Rev Med Pharmacol Sci; 2019 May; 23(9):4027-4032. PubMed ID: 31115032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Levosimendan on cardiac function, size and strain in heart failure patients.
    Beitzke D; Gremmel F; Senn D; Laggner R; Kammerlander A; Wielandner A; Nolz R; Hülsmann M; Loewe C
    Int J Cardiovasc Imaging; 2021 Mar; 37(3):1063-1071. PubMed ID: 33103224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial.
    Comín-Colet J; Manito N; Segovia-Cubero J; Delgado J; García Pinilla JM; Almenar L; Crespo-Leiro MG; Sionis A; Blasco T; Pascual-Figal D; Gonzalez-Vilchez F; Lambert-Rodríguez JL; Grau M; Bruguera J;
    Eur J Heart Fail; 2018 Jul; 20(7):1128-1136. PubMed ID: 29405611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of levosimendan on ventricular remodelling in patients with left ventricular systolic dysfunction: a meta-analysis.
    Wang X; Zhao XZ; Wang XW; Cao LY; Lu B; Wang ZH; Zhang W; Ti Y; Zhong M
    ESC Heart Fail; 2024 Jun; 11(3):1352-1376. PubMed ID: 38419326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Safety and efficacy of the early administration of levosimendan in patients with acute non-ST-segment elevation myocardial infarction and elevated NT-proBNP levels: An Early Management Strategy of Acute Heart Failure (EMS-AHF)].
    Xu F; Bian Y; Zhang GQ; Gao LY; Liu YF; Liu TX; Li G; Song RX; Su LJ; Zhou YJ; Cui JY; Yan XL; Guo FM; Zhang HY; Li QH; Zhao M; Ma LK; You BA; Wang G; Kong L; Ma JL; Zhou XF; Chang ZL; Tang ZY; Yu DY; Cheng K; Xue L; Li X; Pang JJ; Wang JL; Zhang HT; Yu XZ; Chen YG
    Zhonghua Nei Ke Za Zhi; 2023 Apr; 62(4):374-383. PubMed ID: 37032132
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failure.
    Parissis JT; Adamopoulos S; Farmakis D; Filippatos G; Paraskevaidis I; Panou F; Iliodromitis E; Kremastinos DT
    Heart; 2006 Dec; 92(12):1768-72. PubMed ID: 17105880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictive value of QRS duration in response to levosimendan therapy in patients with decompensated heart failure.
    Cetin M; Uçar O; Cicekçioğlu H; Güven Cetin Z; Sahin M; Vasfi Ulusoy F; Aydoğdu S
    Acta Cardiol; 2012 Jun; 67(3):317-23. PubMed ID: 22870740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; Palma dos Reis R
    Clin Cardiol; 2013 Nov; 36(11):677-82. PubMed ID: 23929789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Effectiveness and Safety of Intermittent, Repeated, or Continuous Use of Levosimendan, Milrinone, or Dobutamine in Patients With Advanced Heart Failure: A Network and Single-Arm Meta-analysis.
    Zhang X; Wang Z; Zhang L; Zhao X; Han Y
    J Cardiovasc Pharmacol; 2024 Jul; 84(1):92-100. PubMed ID: 38547524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levosimendan Improves Clinical Outcomes of Refractory Heart Failure in Elderly Chinese Patients.
    Zhang D; Yao Y; Qian J; Huang J
    Med Sci Monit; 2015 Aug; 21():2439-45. PubMed ID: 26289557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of repeated infusion of levosimendan in outpatients with advanced heart failure: a real-world experience.
    Masarone D; Valente F; Verrengia M; Ammendola E; Gravino R; D'Alterio G; Petraio A; Pacileo G
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):919-921. PubMed ID: 33017124
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure.
    Lunghetti S; Palmerini E; Urselli R; Maffei S; Guarino E; Focardi M; Mondillo S; Favilli R
    Cardiol J; 2011; 18(5):532-7. PubMed ID: 21947989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
    Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
    Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.